Clinical Areas of Expertise

Clinical Areas of Expertise

Learn More

Physician Referral

Physician Referral

Learn More

Google Scholar

Google Scholar

Learn More

Recent Publications

Recent Publications

Learn More

Clinical Resources

Clinical Resources

Learn More

Clinical Team Opportunities

Clinical Team Opportunities

Learn More

Clinical Areas of Expertise

Anemia

Google Scholar

Dr. Michael Tarantino

Dr. Michael Tarantino

Google Scholar

Dr. Jonathan Roberts

Dr. Jonathan Roberts

Google Scholar

Dr. Maria Espanol

Dr. Maria Espanol

Google Scholar

Recent Publications

Name of ArticleDateWebsite/ PublicationBCDI Author/Contributor
The Roadmap to Integrate Diversity, Equity, and Inclusion in Hematology Clinical Trials: An American Society of Hematology Initiative12/9/2024Read MoreDr. Roberts
Comparing BAT and Beighton Scores in Patients with ITP: A Retrospective Observational Cohort Study11/5/2024Read MoreDr. Tarantino, Sarah Kreitzer, Nikki Barclay
Durability of Treatment Free Platelet Response in Children with Chronic Immune Thrombocytopenic Purpura Previously Treated with Romiplostim11/5/2024Read MoreDr. Tarantino, Dr. Mistretta, Kristin Ansteatt, Sarah Kreitzer, Nikki Barclay
Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim11/5/2024Read MoreDr. Tarantino
Indirect Comparison of the Efficacy and Therapy-Related Costs of a Pharmacokinetic and Individualized Prophylaxis Regimen with Simoctocog Alfa Versus Other Extended-Half Life Factor VIII Concentrates11/5/2024Read MoreDr. Tarantino
Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses from a Prospective Phase 4 Study11/5/2024Read MoreDr. Tarantino
The Roadmap to Integrate Diversity, Equity, and Inclusion in Hematology Clinical Trials: An ASH Initiative Submitted on Behalf of the Entire Roadmap to Improve DEI in Clinical Trials Working Group11/5/2024Read MoreDr. Roberts
Short Term Health-Related Quality of Life Change in Adults with Sickle Cell Disease11/5/2024Read MoreDr. Roberts
Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database11/5/2024Read MoreDr. Roberts
Athn 10 - Novel Variants in Persons with Rare Coagulation Disorders across Hemophilia Treatment Centers in the United States11/5/2024Read MoreDr. Roberts
Improved prevention of bleeding episodes with emicizumab in 3 patients with concomitant hemophilia A and von Willebrand disease10/1/2024Read MoreDr. Tarantino, Dr. Roberts, Kristin Ansteatt
Hereditary Antithrombin Deficiency Pilot Project Registry from the American Thrombosis and Hemostasis Network (ATHN)8/14/2024Read MoreDr. Tarantino, Dr. Roberts
Prevalence and characterization of anti-VWF antibodies in a population of subjects with type 3 VWD8/1/2024Read MoreDr. Roberts
Costs and Impact of Disease in Adults with Sickle Cell Disease: A Pilot Study5/22/2024Read MoreDr. Roberts
Retrospective chart review of GI bleeding in people with von Willebrand disease5/15/2024Read MoreDr. Roberts
Practical Challenges Associated with Efanesoctocog Alfa (ALTUVIIIO) Prophylaxis in a 19-month-old4/29/2024Read MoreDr. Mistretta, Dr, Espanol, Dr. Tarantino, Dr. Roberts, Dane Christ, Maureen Jones
The common VWF variant p. Y1584C: detailed pathogenic examination of an enigmatic sequence change3/1/2024Read MoreDr. Roberts
The Evolution of Hemophilia Therapeutics: An Illustrated Review1/3/2024Read MoreDr. Espanol, Dr. Mistretta, Dr. Roberts, Dr. Tarantino
Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD1/1/2024Read MoreDr. Tarantino, Dr. Roberts
The common VWF variant p.Y1584C: detailed pathogenic examination of an enigmatic sequence change11/30/2023Read MoreDr. Roberts
Clinical Outcomes of Noninhibitor Patients with Hemophilia a Switching from Prophylaxis with Factor VIII to Emicizumab: A Meta-Analysis of Real-World Evidence Studies11/28/2023Read MoreDr. Tarantino
The Effects of Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, on Bleeding Symptoms and Health-Related Quality of Life in Patients with Immune Thrombocytopenia11/28/2023Read MoreDr. Tarantino
Interim Analysis of Treatment Satisfaction from a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag or Romiplostim to Avatrombopag11/28/2023Read MoreDr. Tarantino
Interim Analysis of Platelet Response in a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA)11/28/2023Read MoreDr. Tarantino
Matching-Adjusted Indirect Comparison of Personalized Prophylaxis with Simoctocog Alfa Versus Standard Prophylaxis with Efanesoctocog Alfa in Adults with Severe Hemophilia a11/28/2023Read MoreDr. Tarantino
Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia11/28/2023Read MoreDr. Tarantino
Matching-Adjusted Indirect Comparison between Personalized Prophylaxis with Simoctocog Alfa Versus Standard Prophylaxis with Emicizumab in Adults with Hemophilia a11/28/2023Read MoreDr. Tarantino
Prophylaxis and Treatment of Bleeding or Thrombosis with Fibrinogen Concentrate (Fibryga) in Patients with Congenital Hypofibrinogenemia or Dysfibrinogenemia11/28/2023Read MoreDr. Tarantino, Dr. Mistretta, Kristin Ansteatt
Identifying Ideal Individuals for PK-Guided Dosing; Recreational Risks and Elevated Breakthrough Bleeding11/28/2023Read MoreDr. Roberts
Association of Health-Related Quality of Life and Work Productivity with Clinical Characteristics in Adults with Sickle Cell Disease11/28/2023Read MoreDr. Roberts
Adherence to Clotting Factor Treatment and Association with Bleeding and Health-Related Quality of Life in Persons with Hemophilia11/28/2023Read MoreDr. Roberts
Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method11/01/2023Read MoreDr. Tarantino
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study10/18/2023Read MoreDr. Tarantino
Characterization of copy-number variants in a large cohort of patients with von Willebrand disease reveals a relationship between disrupted regions and disease type10/1/2023Read MoreDr. Roberts
Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method8/16/2023Read MoreDr. Tarantino
Real‐world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non‐interventional, post‐authorization safety study8/16/2023Read MoreDr. Tarantino
Effects of PK‐guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A8/8/2023Read MoreDr. Roberts
A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.6/20/2023Read MoreDr. Tarantino
Plasma gastric biomaker evaluation with avatrombopag dosing in patients with chronic immune thrombocytopenia in phase 3 trials6/6/2023Read MoreDr. Tarantino
New directions to develop therapies for people with hemophilia6/3/2023Read MoreDr. Tarantino
Variability in International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool (ISTH-BAT) score with normal aging in healthy females: contributory factors and clinical significance4/1/2023Read MoreDr. Roberts
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research to advance the health of people with inherited bleeding disorders with the potential to menstruate3/15/2023Read MoreAmanda Kilgore
Trends in prescribing practices for management of haemophilia: 1999–20213/15/2023Read MoreDr. Roberts
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders3/15/2023Read MoreDr. Tarantino
Depression and anxiety in persons with von Willebrand disease3/1/2023Read MoreDr. Roberts
A need to increase von Willebrand disease awareness: vwdtest.com – A global initiative to help address this gap3/1/2023Read MoreDr. Roberts

Clinical Resources

BCDI works alongside many national healthcare experts when creating guidelines for treatment, care and communication for our patients. We believe it is important for primary care providers and referring providers to have access to valuable community resources. Please see the below resources to learn more.

OrganizationWebsite
National Bleeding Disorders Foundation's Medical and Scientific Advisory Council (MASAC)Read More
Platelet Disorder Support AssociationRead More
American Thrombosis and Hemostasis NetworkRead More
Centers for Disease Control and PreventionRead More

Clinical Team Opportunities

Job PositionLocation
Staff HematologistPeoria, IL